Oral Passive Immunization With Plasma-Derived Polyreactive Secretory-Like IgA/M Partially Protects Mice Against Experimental Salmonellosis.

Details

Ressource 1Download: 30619327_BIB_A2CEE9ACDB57.pdf (2213.74 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_A2CEE9ACDB57
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Oral Passive Immunization With Plasma-Derived Polyreactive Secretory-Like IgA/M Partially Protects Mice Against Experimental Salmonellosis.
Journal
Frontiers in immunology
Author(s)
Corthésy B., Monnerat J., Lötscher M., Vonarburg C., Schaub A., Bioley G.
ISSN
1664-3224 (Electronic)
ISSN-L
1664-3224
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Volume
9
Pages
2970
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Abstract
Secretory immunoglobulins have a critical role in defense of the gastrointestinal tract and are known to act by preventing bacterial acquisition. A stringent murine model of bacterial infection with Salmonella enterica Typhimurium was used to examine protection mediated by oral passive immunization with human plasma-derived polyreactive IgA and IgM antibodies (Abs) reconstituted as secretory-like immunoglobulins (SCIgA/M). This reagent has been shown to trigger Salmonella agglutination and to limit the entry of bacterium into intestinal Peyer's patches via immune exclusion. We now demonstrate that upon administration into ligated intestinal loops, SCIgA/M properly anchors in the mucus and is protected from degradation to a better extent that IgA/M or IgG. Moreover, prophylactic oral administration of SCIgA/M before intragastric infection of mice with a virulent strain of S. enterica Typhimurium allows to protect infected animals, as reflected by reduced colonization of both mucosal and systemic compartments, and conserved integrity of intestinal tissues. In comparison with IgA/M or IgG administration, SCIgA/M provided the highest degree of protection. Moreover, such protective efficacy is also observed after therapeutic oral delivery of SCIgA/M. Either prophylactic or therapeutic treatment with passively delivered SCIgA/M ensured survival of up to 50% of infected mice, while untreated animals all died. Our findings unravel the potential of oral passive immunization with plasma-derived polyreactive SCIgA/M Abs to fight gastrointestinal infections.
Keywords
Administration, Oral, Animals, Disease Models, Animal, Female, Humans, Immunization, Passive/methods, Immunoglobulin A, Secretory/administration & dosage, Immunoglobulin A, Secretory/blood, Immunoglobulin A, Secretory/isolation & purification, Immunoglobulin M/administration & dosage, Immunoglobulin M/blood, Immunoglobulin M/isolation & purification, Intestinal Mucosa/immunology, Intestinal Mucosa/microbiology, Mice, Mice, Inbred BALB C, Peyer's Patches/immunology, Peyer's Patches/microbiology, Plasma/immunology, Salmonella Infections/immunology, Salmonella Infections/microbiology, Salmonella Infections/therapy, Salmonella typhimurium/immunology, Salmonella typhimurium/pathogenicity, Treatment Outcome, Salmonella, passive immunization, protection, secretory IgA, secretory IgM
Pubmed
Web of science
Open Access
Yes
Create date
03/02/2019 15:13
Last modification date
16/12/2019 6:19
Usage data